RxDoctor Payments Data

John Harb, MD

Urology · Livonia, MINPI 1811967334

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Medtronic at 43.5% of the total. Reporting peaked in 2024 at $6,134 and has fallen 70.1% since, to $1,837 in 2025. Among urology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,116in general payments, 2019–2025

Across 359 payments — averaging $58.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Neotract Inc.$3K
  • Teleflex LLC$2K
  • Coloplast$2K
  • Astellas Pharma US Inc$904
  • Pfizer$692
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$5,00024%
  • Travel & lodging$5,44326%
  • Food & beverage$10,21448%
  • Education$4592%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,116 in reported general payments places this provider in the 90th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$334,915
Medicare patients
613
Services billed
4,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron82$51,253
MyrbetriqMirabegron68$45,737
Mirabegron ErMirabegron16$8,674
Tamsulosin Hcl353$4,557
Oxybutynin Chloride ErOxybutynin Chloride125$2,138
Solifenacin Succinate46$2,010
Tolterodine Tartrate ErTolterodine Tartrate17$1,670
Ciprofloxacin Hcl200$1,352
Potassium Citrate ErPotassium Citrate13$1,274
Estradiol20$1,268
Finasteride58$914
Cephalexin133$861
Alfuzosin Hcl ErAlfuzosin Hcl22$523
NitrofurantoinNitrofurantoin Macrocrystal11$434
Nystatin29$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$45$51,25382 claims
Astellas Pharma US IncMyrbetriq$904$45,73768 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 urology providers in Michigan.

Other urology in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →